Category - News

Markets

SVB Leerink starts MannKind at OP; PT $3

SVB Leerink initiated coverage of MannKind (NASDAQ:MNKD) with an “outperform” rating and a 12-month price target of $3. The stock closed at $1.77 on March 1. Analyst Dr. Pasha Sarraf writes that his rating is based on...

March 4, 2019

Markets

AGP starts OpGen at buy; PT $2.30

AGP/Alliance Global Partners launched coverage of OpGen (NASDAQ:OPGN) with a “buy” rating and price target of $2.30. The stock closed at $1.48 on March 1. “OpGen’s approach to antibiotic resistance identification...

March 4, 2019

Developments

Genetic meta-analysis identifies four new genetic variants associated with Alzheimer’s disease

A genome-wide association study of 94,000 individuals has identified four new genetic variants that play a role in the development of late-onset Alzheimer’s disease (AD). Conducted by an international consortium of...

March 1, 2019

Developments

Novavax Phase 3 ResVax trial misses primary endpoint

Novavax (NASDAQ:NVAX) reported that its Phase 3 PREPARE studyfor ResVax, a RSV (respiratory syncytial virus) F vaccine, did not meet its primary objective of preventing medically significant RSV lower respiratory tract...

March 1, 2019

Developments

Guardant Health liquid biopsy beats tissue testing in advanced non-small cell lung cancer

In a prospective multi-center study of 282 newly diagnosed non-small cell lung cancer patients, Guardant Health’s (NASDAQ:GH) liquid biopsy genomic assay, Guardant360, outperformed standard-of-care tissue testing in...

March 1, 2019

Markets

HCW starts Albireo Pharma at buy; PT $62

H.C. Wainwright launched coverage of Albireo Pharma (NASDAQ:ALBO) with a “buy” rating and $27 price target. The stock closed at $26.80 on Feb. 27. Albireo is focused on rare pediatric and adult cholestatic diseases...

February 28, 2019

Markets

Dawson James starts Caladrius Biosciences at buy; PT $7

Dawson James Securities initiated coverage of Caladrius Biosciences (NASDAQ:CLBS) with a “buy” rating and price target of $7. The stock closed at $4.20 on Feb. 26. The focus at Caladrius is cell therapy, with an...

February 27, 2019

Markets

Corindus Vascular Robotics closes private placement

Corindus Vascular Robotics (NYSE American:CVRS) privately sold 10,872,716 of its common shares at a price of $1.3796 each to a large institutional investor for gross proceeds of about $15-million. Net proceeds of about...

February 26, 2019

Developments

BeyondSpring to report positive Plinabulin CIN data at ASCO-SITC

BeyondSpring (NASDAQ: BYSI) announced new clinical results from its Study 106 program for lead asset Plinabulin, which demonstrates that combining Plinabulin with Neulasta not only improves overall efficacy for...

February 26, 2019

Developments

Titan Pharma in pact with AllianceRx Walgreens Prime to expand patient access to Probuphine

Titan Pharmaceuticals (NASDAQ:TTNP) entered a specialty pharmacy distribution and services agreement with AllianceRx Walgreens Prime to expand patient access to its Probuphine six-month implant for the maintenance...

February 25, 2019

Category - News

Subscribe